Match!
Joshua M. Diamond
University of Pennsylvania
Intensive care medicineLungLung transplantationPrimary Graft DysfunctionMedicine
139Publications
25H-index
2,660Citations
What is this?
Publications 148
Newest
#1Brittany C. Koons (UPenn: University of Pennsylvania)
#2John R. Greenland (UCSF: University of California, San Francisco)H-Index: 11
Last. Jonathan P. Singer (UCSF: University of California, San Francisco)H-Index: 19
view all 4 authors...
Abstract Frailty is a clinical state of vulnerability to stressors resulting from cumulative alterations in multiple physiological and molecular systems. Frailty assessment in patients with chronic disease is useful for identifying those who are at increased risk for poor clinical and patient reported outcomes. Due to biobehavioral changes purported to cause both frailty and certain chronic lung diseases, patients with lung disease appear susceptible to frailty and prone to developing it decades...
Source
Purpose Rates of deep vein thrombosis (DVT) range from 20-60% in patients undergoing extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome. Data on the rates of DVT in lung transplant recipients bridged with ECMO is limited. The objective of this study was to report incidence and outcomes, including use of anticoagulation and subsequent bleeding rates, of DVT in ECMO-bridged transplant recipients. Methods This was a single center retrospective cohort study of all adu...
Source
#2Pali D. Shah (Johns Hopkins University)H-Index: 15
Last. A. MarishtaH-Index: 2
view all 23 authors...
Purpose Primary Graft Dysfunction (PGD) is a risk factor for Chronic Lung Allograft Dysfunction (CLAD). However, this association requires further examination for better risk stratification of PGD patients. Donor-derived cell-free DNA (%ddcfDNA) is a biomarker for lung allograft injury and early post-transplant %ddcfDNA levels may predict long-term outcomes. This study leverages %ddcfDNA to assess the association of PGD and allograft injury, as well as the ability of %ddcfDNA to identify PGD pat...
Source
Source
Source
Source
Source
Source
#1Ashwin S. Nathan (Leonard Davis Institute of Health Economics)H-Index: 8
#2Catherine Blebea (UPenn: University of Pennsylvania)
Last. Andrew M. Courtwright (HUP: Hospital of the University of Pennsylvania)H-Index: 9
view all 9 authors...
INTRODUCTION: One-year post-transplant survival is a significant quality measure for solid organ transplant programs in the United States. It is not known whether the use of this metric is associated with changes in life-sustaining clinical practices that would delay mortality for solid organ recipients until just beyond the one-year time point. METHODS: We compared trends in mortality in the time period immediately preceding the one-year post-transplant mark compared to the period immediately a...
Source
#1Osnat Shtraichman (UPenn: University of Pennsylvania)
#2Joshua M. Diamond (UPenn: University of Pennsylvania)H-Index: 25
AbstractIntroduction: Lung transplantation remains an important treatment for patients with end stage lung disease. Chronic lung allograft dysfunction (CLAD) remains the greatest limiting factor fo...
Source
12345678910